The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer.

This document discusses the investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) in the treatment of metastatic kidney cancer. The article highlights the increasing incidence of renal cell carcinoma (RCC) in the older population and the challenges of offering invasive therapies to elderly patients. SABR has emerged as a noninvasive alternative, with studies showing promising results in terms of oncologic outcomes and renal function preservation. The document also mentions ongoing clinical trials investigating the combination of SABR with immune checkpoint inhibitors and tyrosine kinase inhibitors. The authors emphasize the advancements in radiation oncology and radiobiology that have made precise delivery of high-dose radiation possible, and they anticipate the availability of new radiotracers and treatment modalities in this field. [Extracted from the article]